TEL AVIV, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Moody's Investor Services (“Moody's”) has raised the company's corporate credit rating to Ba1, outlook stable; from Ba2, outlook positive. Moody's report cites the Company's strengths which include significant global scale, ongoing growth in the company’s branded franchises, stabilization of the company’s generics business, focus on debt reduction and resolution of various legal liabilities htt ...

The Company achieved a 29% reduction in absolute scope 1 and 2 greenhouse gas emissions from 2019 levels, surpassing its target of 25% by 2025, ahead of scheduleTeva launched two new programs to help people around the world access the medicines they need, for a total of nine programs, surpassing its target of eight programs by 2025More than 99% of Teva employees were trained on compliance and ethics, and more than 40% of its significant suppliers were evaluated for sustainability performanceTeva received im ...

Teva Pharmaceutical Industries (NYSE: TEVA ) is one of those stocks that’s been put to the test. For years it’s been a company people loved to hate—opioid lawsuits, a mountain of debt, brutal competition in the generics market. So it’s not exactly shockingWith over 15 years of experience in the markets and a degree in economics, I focus on breaking down companies with clarity and discipline. My goal is to give individual investors a straightforward, honest view—what’s working, what isn’t, and where the risk ...

Teva Pharmaceutical Industries (TEVA) reported first-quarter 2025 adjusted earnings of 52 cents per share, which beat the Zacks Consensus Estimate of 47 cents. Adjusted earnings rose 8% year over year, driven by higher operating profits.Revenues for the first quarter were $3.89 billion, which missed the Zacks Consensus Estimate of $3.97 billion. However, total revenues rose 2% from the year-ago quarter on a reported basis and 5% on a constant currency basis.Top-line growth was driven by higher revenues from ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-16174 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Israel Not ...

Shares of Teva Pharmaceutical (TEVA 8.44%) are surging on Wednesday. The company's stock is up 9.2% as of 1:15 p.m. ET and was up as much as 9.5% earlier in the day. The leg up comes as the S&P 500 is up 0.4% and the Nasdaq Composite is losing 0.1% on the day so far.The Israel-based pharmaceutical company reported strong Q1 earnings today and raised its full-year profit guidance.Earnings beat despite revenue missTeva reported Q1 adjusted earnings per share (EPS) of $0.52, solidly beating Wall Street's targe ...

Teva Pharmaceutical Industries Ltd TEVA stock is trading higher on Wednesday after the company's first- quarter 2025 financial results. Here are the details. Teva reported revenue of $3.89 billion, up 5% year-over-year, missing analyst estimates of $4.00 billion, according to Benzinga Pro. The increase was driven by higher revenues from Austedo in the U.S. segment. Austedo's worldwide revenues were $411 million in Q1 2025, an increase of 39% in local currency terms compared to Q1 2024. U.S. Austedo revenues ...

About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup ...

Teva Pharmaceutical Industries Ltd. (TEVA) reported $3.89 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 1.9%. EPS of $0.52 for the same period compares to $0.48 a year ago.The reported revenue represents a surprise of -1.92% over the Zacks Consensus Estimate of $3.97 billion. With the consensus EPS estimate being $0.47, the EPS surprise was +10.64%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street exp ...

Teva Pharmaceutical Industries (TEVA) Q1 2025 Earnings Call May 07, 2025 08:00 AM ET Speaker0 Hello, and welcome to the Q1 twenty twenty five Teva Pharmaceutical Industries Limited Earnings Conference Call. My name is Alex, and I'll be coordinating the call today. I'll now hand it over to your host, Christopher Stivo, Head of Investor Relations to begin. Please go ahead. Speaker1 Thank you, Alex. Good morning, everyone. In the course of this call, we're going to be making some forward looking statements. An ...